argenx vs IDEXX Laboratories

argenx (ARGX), health care, and IDEXX Laboratories (IDXX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

argenx is worth $59.6B on the stock market and IDEXX Laboratories $54.8B: argenx is valued at 9% more. argenx trades at 32.8 times earnings and IDEXX Laboratories at 46.9; operating margins in their latest fiscal years were 25.4% and 31.6%. Over the past year argenx's share price has moved +3.53% and IDEXX Laboratories's +4.54%.

Key facts

argenx market value
$59.6B
IDEXX Laboratories market value
$54.8B
argenx P/E
32.8
IDEXX Laboratories P/E
46.9
argenx revenue
$4.2BFY to 2025-12-31
IDEXX Laboratories revenue
$4.3BFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

argenx vs IDEXX Laboratories: every measure side by side
Measure argenx IDEXX Laboratories
SectorHealth CareHealth Care
Country Belgium United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$59.6Bhigher$54.8Blower
Revenue$4.2Blower$4.3Bhigher
Earnings$1.3Bhigher$1.1Blower
Employees1,863lower11,000higher
Total assets$8.7Bhigher$3.4Blower
Valuation
P/E32.8lower46.9higher
P/S14.3higher12.7lower
P/B—29.3
Dividend yield—0.00%
Profitability
Operating margin25.4%lower31.6%higher
Balance sheet
Net assets$7.3Bhigher$1.6Blower
Total liabilities$1.4Blower$1.7Bhigher
Total debt—$450M
Cash on hand$3.5Bhigher$180.1Mlower
Price change
Today-0.42%higher-0.74%lower
1 year+3.53%lower+4.54%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (1)

argenx only (1)

Percentages are each holding's share of that investor's reported portfolio (under "Both": argenx / IDEXX Laboratories). Who owns ARGX · Who owns IDXX

Further comparisons

Learn

Questions and answers

Which is bigger, argenx or IDEXX Laboratories?

By market value, argenx is the larger: $59.6B against $54.8B for IDEXX Laboratories. By revenue in its latest fiscal year, IDEXX Laboratories is the larger: $4.3B against $4.2B for argenx.

Which has the higher P/E ratio?

IDEXX Laboratories: 46.9, against 32.8 for argenx. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

IDEXX Laboratories: 31.6%, against 25.4% for argenx. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both argenx and IDEXX Laboratories?

In their latest 13F filings, Ron Baron holds both.

Cite this page

Funkfolio, “argenx vs IDEXX Laboratories”, data as of 17 November 2026. https://funkfolio.com/compare/argx-vs-idxx

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.